Is PMCB or PRAX more undervalued in 2026?

CirclFi compares PharmaCyte Biotech, Inc. (PMCB) and Praxis Precision Medicines, Inc (PRAX) using 13 institutional-grade valuation models. PMCB has a Quality of Company score of 5.1/10 while PRAX scores 5.6/10.

Which is a better buy — PMCB or PRAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PMCB and PRAX valuations compare?

PMCB at $0.86 and PRAX at $352.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PMCB vs PRAX Valuation Comparison 2026 — Intrinsic Value Analysis

PMCB

Biotechnology

PharmaCyte Biotech, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$0.86

Last close

Models

4/13

Active

PRAX

Biotechnology

Praxis Precision Medicines, Inc

Quality

5.6

out of 10

Value Trap

SAFE

Price

$352.63

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	PMCB Fair Value	PMCB Upside	PRAX Fair Value	PRAX Upside
Bayesian DCF	Intrinsic	—	—	$116.77	-66.9%
Earnings Power Value	Intrinsic	—	—	$151.65	-56.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$5.13	+498.5%	$21.52	-93.9%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.46	+186.9%	$45.59	-87.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PMCB vs PRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PMCB vs PRAX — Which Stock Is More Undervalued?

PRAX scores higher with a 5.6/10 quality rating vs PMCB's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PharmaCyte Biotech, Inc. (PMCB) and Praxis Precision Medicines, Inc (PRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PMCB currently trades at $0.86 with a QOC of 5.1/10, while PRAX trades at $352.63 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).